Biodrugs

Papers
(The TQCC of Biodrugs is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Therapeutic siRNA: State-of-the-Art and Future Perspectives161
Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future80
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic63
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer55
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins55
Dengue Vaccines: An Update53
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease46
Teserpaturev/G47Δ: First Approval43
European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption42
Administration of CD4+CD25highCD127−FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study41
Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond40
CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success38
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis37
RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis33
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities31
Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration30
Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering29
SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin27
Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update27
Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis27
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants26
Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy26
Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study25
Cryopreservation of NK and T Cells Without DMSO for Adoptive Cell-Based Immunotherapy23
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies23
Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial23
Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale23
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management22
Plant-Derived Human Vaccines: Recent Developments22
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience21
Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project21
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing20
Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets20
Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe19
Malaria Vaccines: Progress to Date19
New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database19
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine17
Targeting IL-36 in Inflammatory Skin Diseases17
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)17
A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study16
Vaccine-Associated Enhanced Viral Disease: Implications for Viral Vaccine Development16
Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy16
Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey16
Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review15
A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study14
Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Doub14
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active 14
Impact of Obesity on Response to Biologic Therapies in Patients with Inflammatory Bowel Diseases13
Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design13
Biosimilar Perceptions Among Healthcare Professionals and Commercial Medical Benefit Policy Analysis in the United States13
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis13
Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)13
Enhancing the Response Rate to Recombinant Uricases in Patients with Gout13
Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines12
Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders12
PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras12
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment12
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?12
Outer Membrane Vesicle Vaccine Platforms12
0.033646106719971